Compare Roblox Corp (RBLX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs BIO-TECHNE Corp — how do they compare? Roblox Corp trades at $44.55 (market cap $32.02B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Roblox Corp is far larger — about 2.8× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| RBLX | TECH | |
|---|---|---|
Market Cap | $32.02B | $11.34B |
Sector | Media | Health |
52-Week High | $141.56 | $72.48 |
52-Week Low | $35.54 | $43.31 |
Enterprise Value | $30.84B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RBLX trades at $44.82, up 3.49% today, near the consensus price target of $45.71. The stock shows bullish technical signals with strong support at $43 and resistance at $46. Revenue growth is robust, rising to $4.89B in 2025, but net losses persist at -$1.07B. Recent news highlights regulatory scrutiny in the EU and Australia over child safety, alongside positive economic impact from creator earnings.
Outlook remains mixed: strong revenue growth and cash flow improvement support long-term potential, but profitability challenges and regulatory risks weigh on sentiment. Analysts are divided, with 44.7% recommending buy. The key catalyst is achieving sustained profitability amid expanding user engagement.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
